Base editing is a type of genomic editing technology that allows for the direct conversion of one DNA base into another without requiring double-strand breaks in the DNA. This method uses a fusion protein consisting of a deaminase enzyme and a catalytically impaired Cas9 nuclease.
Base editing addresses the limitations of traditional CRISPR-Cas9 methods that require double-strand breaks in DNA, which can introduce off-target effects and genomic instability. It provides a more precise way to correct genetic mutations associated with various diseases.
The deaminase enzyme, which can convert specific bases (e.g., cytosine to uracil), is fused with an inactive version of the Cas9 enzyme. This fusion protein targets the DNA sequence of interest, and the deaminase converts the target base, followed by the cell's natural repair mechanisms converting the uracil into a different base (typically adenine).
Manufacturing base editors involves cloning the deaminase enzyme into an inactive Cas9 backbone using molecular biology techniques such as PCR and plasmid construction. The resulting constructs are then transformed into appropriate host cells for production.
The build process includes designing the fusion protein, expressing it in bacterial or mammalian cell cultures, purifying the protein, and validating its activity through in vitro and in vivo assays.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.